A Review of the Efficacy of Anastrozole in Postmenopausal Women with Advanced Breast Cancer with Visceral Metastases
Authors:
- 1 December 2003
- journal article
- review article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 82 (3) , 215-222
Abstract
Tumors that have spread to the liver or lungs (visceral metastases) are associated with a worse prognosis than tumors in soft tissue and bone only. Here we review available efficacy data to address...Keywords
This publication has 25 references indexed in Scilit:
- Anastrozole (‘Arimidex’) blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancerBritish Journal of Cancer, 2002
- Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinomaCancer, 2001
- First-line endocrine therapy in postmenopausal (PM) patients (pts) with advanced breast cancer (ABC) and visceral metastases (mets): Anastrozole (AN) versus tamoxifen (TAM)European Journal of Cancer, 2001
- Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized TrialJournal of Clinical Oncology, 2000
- A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer *European Journal of Cancer, 1996
- Aromatase inhibitor development for treatment of breast cancerBreast Cancer Research and Treatment, 1995
- Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy gradingBritish Journal of Cancer, 1990
- Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients.Journal of Clinical Oncology, 1987
- Estrogen Receptor and Natural Course of Breast CancerAnnals of Surgery, 1976
- A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474British Journal of Cancer, 1971